Další formáty:
BibTeX
LaTeX
RIS
@article{1443078,
author = {Kováčová, Júlia and Poprach, A. and Buchler, T. and Cho, W.C. and Slabý, Ondřej},
article_location = {BERLIN},
article_number = {9},
doi = {http://dx.doi.org/10.1515/cclm-2017-0861},
keywords = {miRNAs; prediction; renal cell carcinoma; sunitinib; tyrosine kinase inhibitor},
language = {eng},
issn = {1434-6621},
journal = {Clinical Chemistry and Laboratory medicine},
title = {MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma},
url = {https://www.degruyter.com/view/j/cclm.2018.56.issue-9/cclm-2017-0861/cclm-2017-0861.xml},
volume = {56},
year = {2018}
}
TY - JOUR
ID - 1443078
AU - Kováčová, Júlia - Poprach, A. - Buchler, T. - Cho, W.C. - Slabý, Ondřej
PY - 2018
TI - MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
JF - Clinical Chemistry and Laboratory medicine
VL - 56
IS - 9
SP - 1426-1431
EP - 1426-1431
PB - WALTER DE GRUYTER & CO
SN - 14346621
KW - miRNAs
KW - prediction
KW - renal cell carcinoma
KW - sunitinib
KW - tyrosine kinase inhibitor
UR - https://www.degruyter.com/view/j/cclm.2018.56.issue-9/cclm-2017-0861/cclm-2017-0861.xml
N2 - Renal cell carcinoma (RCC) accounts for 2%-3% of all malignant tumours. The first-choice treatment in metastatic RCC (mRCC) patients is tyrosine kinase inhibitors (TKIs). Although TKIs may prolong survival of the treated patients who are not primary resistant, almost all of them will eventually develop secondary resistance to the treatment after a progression-free period. To predict treatment response, thus, we need efficient biomarkers for rational indication of TKIs in mRCC. MicroRNAs (miR-NAs) not only play important roles in the pathogenesis of many cancers, including RCC but also have been shown to serve as promising diagnostic, prognostic and predictive biomarkers in various cancers. However, the potential of miRNAs to predict response to therapy with TKIs in mRCC has not yet gained sufficient attention. Because personalisation of the TKIs indication in mRCC presents an important unmet medical need, we summarise research on this topic and give an overall insight on the current knowledge in this field.
ER -
KOVÁČOVÁ, Júlia, A. POPRACH, T. BUCHLER, W.C. CHO a Ondřej SLABÝ. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. \textit{Clinical Chemistry and Laboratory medicine}. BERLIN: WALTER DE GRUYTER \&{}amp; CO, 2018, roč.~56, č.~9, s.~1426-1431. ISSN~1434-6621. Dostupné z: https://dx.doi.org/10.1515/cclm-2017-0861.
|
